Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dupilumab in Netherton Syndrome
NCT04244006Phase 3Terminated
- Sponsor
- Centre hospitalier universitaire de Toulouse
- Start
- Jul 2020
- Primary completion
- Jun 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Netherton syndrome (NS) comparing Dupilumab with Placebo (2 arms). Primary endpoint: Netherton Area Severity Assessment score at week 16. Started Jul 2020; status: terminated.
02
Drugs
03
Conditions
Netherton syndrome (NS)
Beyond the preview
Go deeper on NCT04244006.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04244006.